MEK5-ERK5 pathway associates with poor survival of breast cancer patients after systemic treatments

Oncoscience

Volumn 2, Issue 2, 2015, Pages 99-101

  Miranda, Mariska ^a   Rozali, Esdy ^a   Khanna, Kum Kum ^a   Al Ejeh, Fares ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

Chemo resistance; ERK5 MAPK7; MEK5 MAP2K5; TNBC; Triple negative breast cancer

Indexed keywords

EID: 84958550687     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.135     Document Type: Article

References (7)

1. Yang Q, Lee JD. Targeting the BMK1 MAP kinase pathway in cancer therapy. Clin Cancer Res. 2011;17(11):3527-32.
2. Drew BA, Burow ME, Beckman BS. MEK5/ERK5 pathway: the first fifteen years. Biochimica et biophysica acta. 2012;1825(1):37-48.
3. Al-Ejeh F, Miranda M, Shi W, Simpson PT, Song S, Vargas AC, et al. Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Oncotarget. 2014;5(10):3145-58.
4. Ortiz-Ruiz MJ, Alvarez-Fernandez S, Parrott T, Zaknoen S, Burrows FJ, Ocana A, et al. Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget. 2014;5(22):11308-18.
5. Goh KC, Novotny-Diermayr V, Hart S, Ong LC, Loh YK, Cheong A, et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia. 2012;26(2):236-43.
6. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast cancer research and treatment. 2010;123(3):725-31.
7. Montero JC, Ocana A, Abad M, Ortiz-Ruiz MJ, Pandiella A, Esparis-Ogando A. Expression of Erk5 in early stage breast cancer and association with disease free survival identifies this kinase as a potential therapeutic target. PLoS ONE. 2009;4(5):e5565.